The molecular diagnostics company reported total revenues of $56.7 million in the quarter, and saw its testing volume grow 15 percent over Q3 2016.
Researchers at Aarhus will use Natera's liquid biopsy assay to monitor colorectal cancer patients after surgery and chemotherapy.
The company is collaborating with two UK institutes to assess whether its Signatera ctDNA technology can detect disease recurrence in women treated for breast cancer.
Several commercial NIPT providers in the US said they are planning to participate in the new program.
The company says Panorama is the only NIPT that can tell whether twins are identical or fraternal, which can impact the clinical management of a pregnancy.
Natera said that this research collaboration and others will help it clinically validate its circulating tumor DNA assay Signatera.
The Index gained 4 percent, outperforming the Dow and the Nasdaq, but underperformed the Nasdaq Biotechnology Index, which rose 5 percent.
Natera has entered the oncology space with a ctDNA assay and sees its blood banking service as a way to eventually tap into the consumer genomics space.
Natera ran 17 percent more tests in Q2 than it did in the prior-year period, generating $53.6 million in total revenues.
The Index fell less than 1 percent in July, underperforming the Dow, the Nasdaq, and the Nasdaq Biotechnology Index.
Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.
Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.
Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.
In Science this week: gut microbiome influences liver cancer growth, spread; and more.